Open AccessRisk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy
Author(s) -
I. GarcíaDoval,
G. Carretero,
F. Vanaclocha,
Carlos Montilla,
E. Daudén,
J.L. SánchezCarazo,
M. Alsina,
Enrique HerreraCeballos,
Francisco GómezGarcía,
Marta Ferrán,
J.L. LópezEstebaranz,
Jose-Manuel Hernanz,
I. Belinchón,
Jaime VilarAlejo,
R. Rivera,
J.M. Carrascosa,
Cristina Carazo
Publication year - 2012
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archdermatol.2011.2768
Subject(s) - medicine , psoriasis , adverse effect , incidence (geometry) , randomized controlled trial , cohort , dermatology , physics , optics
To describe the use of systemic therapy for psoriasis (biologic and nonbiologic [classic] drugs) in patients not adequately represented in randomized controlled trials (RCTs) and the risk of serious adverse events (SAEs) in these patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom